The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan.
As of May 29, 50% subjects of this trial has successfully completed the one-year treatment protocol and the remaining 50% subjects are scheduled to complete all treatment by December 2026.
The study is scheduled for unblinding in the first quarter of 2027.